1) Tschoepe D, Schultheiss HP, Kolarov P, et al:Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 88:37-42, 1993
2) Harrison P, Frelinger AL 3rd, Furman MI, et al:Measuring antiplatelet drug effects in the laboratory. Thromb Res 120:323-336, 2007
3) 松原由美子,村田満:抗血小板薬のモニタリング―抗血小板薬の薬効評価の基本的考え方と実際.医学のあゆみ 228:957-961,2009
4) Antithrombotic Trialists' Collaboration:Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86, 2002
5) Crescente M, Di Castelnuovo A, Iacoviello L, et al:Response variability to aspirin as assessed by the platelet function analyzer(PFA)-100. A systematic review. Thromb Haemost 99:14-26, 2008
6) SIEMENS「PFA-100® System」〈http://diagnostics.siemens.com/webapp/wcs/stores/servlet/ProductDisplay~q_catalogId~e_-111~a_catTree~e_100001,1015818~a_langId~e_-111~a_productId~e_182047~a_storeId~e_10001.htm〉 2009/05/28
7) CAPRIE Steering Committee:A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 348:1329-1339, 1996
8) Price MJ, Endemann S, Gollapudi RR, et al:Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29:992-1000, 2008
9) Aleil B, Ravanat C, Cazenave JP, et al:Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 3:85-92, 2005
10) Accumetrics 「VerifyNow P2Y12 Assay」 〈http://www.accumetrics.com/products/vnp2y12.aspx〉2009/06/03